Berrin Tunca

8PUBLICATIONS
32CO-AUTHORS
Haematological tumoursPaediatrics not elsewhere classifiedMolecular targetsEcosystem services (incl. pollination)Natural products and bioactive compounds
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Mar 31, 2026
The MALAT1-EZH2 axis regulates PRC2 activity and promotes the mesenchymal phenotype in pediatric atypical teratoid/rhabdoid tumors.

Melisa Gurbuz, Cagla Tekin, Melis Ercelik

|Feb 25, 2026
Identification of the Philadelphia-like subgroup in Turkish pediatric patients with acute lymphoblastic leukemia.

Ecem Efendi Erdem, Gulsah Cecener, Ufuk Unal

|Jan 30, 2026
Overcoming Intrinsic and Acquired Temozolomide Resistance in Glioblastoma: Fisetin as a Potential Strategy to Enhance Sensitivity via ZEB1 Modulation.

Sena Ferah, Mine Çamlıbel, Melis Erçelik

|May 10, 2023
Olea europaea L. Leaf Extract Attenuates Temozolomide-Induced Senescence-Associated Secretion Phenotype in Glioblastoma.

Melis Erçelik, Berrin Tunca, Seçil Ak Aksoy

|Feb 25, 2023
Olea europaea Leaf Phenolics Oleuropein, Hydroxytyrosol, Tyrosol, and Rutin Induce Apoptosis and Additionally Affect Temozolomide against Glioblastoma: In Particular, Oleuropein Inhibits Spheroid Growth by Attenuating Stem-like Cell Phenotype.

Melis Ercelik, Cagla Tekin, Gulcin Tezcan

|Jul 06, 2022
Early-stage colon cancer with high MALAT1 expression is associated with the 5-Fluorouracil resistance and future metastasis.

Secil Ak Aksoy, Berrin Tunca, Melis Erçelik

Pageof 2

Frequent Collaborators

4 joint publications

Gulcin Tezcan

3 joint publications

Unal Egeli

3 joint publications

Çağla Tekin

3 joint publications

Melis Erçelik